|Poll|May 15, 2015

May Quiz: Geriatric Psychiatry Question 2

What is the potential role of rTMS in treating neuropsychiatric symptoms of neurological disease?

The potential role of rTMS in treating neuropsychiatric symptoms of neurological disease has been expanding, especially in the past decade. Regarding the use of rTMS in Parkinson disease, which of these statements is true?

A. Most rTMS studies have been related to PD
B. Findings have been positive for improved depressive symptoms
C. Relief of global PD symptoms has not been as positive
D. More trials are needed to clarify rTMS efficacy in severely depressed PD patients
E. All of the above are true

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Latest CME

Real Psychiatry 2026
In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

View more
Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?
Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

View more
Optimizing Care for Patients With Tardive Dyskinesia
Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

View more
Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia
Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

View more
Southern California Psychiatry Conference
In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!
(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia
Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

View more
Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder
Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

View more
Jersey City Psychiatry
In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!
Southern Florida Psychiatry Conference
In-Person Event

Southern Florida Psychiatry Conference

December 4-5, 2026

Register now!
Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder
Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

View more
(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia
Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

View more
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us